In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CymaBay Therapeutics Inc.

www.cymabay.com

Latest From CymaBay Therapeutics Inc.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.

 

Policy & Regulation Liver & Hepatic

CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.

Clinical Trials Drug Safety

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.

Comparative Effectiveness Gene Therapy

Genfit Assesses Optimal Elafibranor NASH Combo Therapy Opportunity

As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if a GLP-1 analog or SGLT2 inhibitor would offer the best therapeutic synergy, market potential and partnership opportunity.

Business Strategies Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Metabolex Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CymaBay Therapeutics Inc.
  • Senior Management
  • Sujal Shah, Pres. & CEO
    Patrick J O'Mara, VP, Bus. Dev.
    Charles A McWherter, PhD, SVP, CSO
    Dan Menold, VP, Fin.
    Janet Dorling, Chief Commercial Officer
  • Contact Info
  • CymaBay Therapeutics Inc.
    Phone: (510) 293-8800
    7575 Gateway Blvd., Ste. 110
    Newark, CA 94560
    USA
UsernamePublicRestriction

Register